Compounds > staurosporine
Page last updated: 2024-08-23

staurosporine and imatinib mesylate

staurosporine has been researched along with imatinib mesylate in 29 studies

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (51.72)29.6817
2010's14 (48.28)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Bach, S; Berthelot, P; Bonnet, P; Brachet-Botineau, M; Denevault-Sabourin, C; Gouilleux, F; Logé, C; Oyallon, B; Robert, T; Ruchaud, S; Souab, M; Viaud-Massuard, MC1
Boulton, C; Fabbro, D; Gilliland, DG; Griffin, JD; Kelly, LM; Manley, P; Meyer, T; Weisberg, E1
Amaral, SM; Boulton, CL; Cools, J; Coutre, SE; Curley, DP; DeAngelo, DJ; Duclos, N; Fabbro, D; Gilliland, DG; Gotlib, J; Griffin, JD; Kutok, JL; Lee, BH; Legare, RD; Manley, PW; Marynen, P; Meyer, T; Neuberg, D; Rowan, R; Stone, RM; Stover, EH; Weisberg, E; Williams, IR1
Boulton, C; Gilliland, DG; Griffin, JD; Gu, TL; Mohi, MG; Neel, BG; Neuberg, D; Sternberg, DW1
Adams, JM; Atwell, S; Badger, J; Buchanan, MD; Buchanan, SG; Burley, SK; Feil, IK; Froning, KJ; Gao, X; Hendle, J; Keegan, K; Leon, BC; Müller-Dieckmann, HJ; Nienaber, VL; Noland, BW; Post, K; Rajashankar, KR; Ramos, A; Russell, M1
Cools, J; Debiec-Rychter, M; Dumez, H; Hagemeijer, A; Marynen, P; Mentens, N; Prenen, H; Roesel, J; Sciot, R; Stul, M; Van Oosterom, A; Vranckx, H; Wasag, B1
Adelsperger, J; Clark, JJ; Fabbro, D; Gilliland, DG; Griffin, JD; Growney, JD; Stone, R1
Cools, J1
Aichberger, KJ; Böhm, A; Derdak, S; Fabbro, D; Gleixner, KV; Gruze, A; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P1
Catley, L; Fabbro, D; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; Manley, PW; Moreno, D; Podar, K; Ray, A; Weisberg, E; Wright, RD1
Agis, H; Aichberger, KJ; Gleixner, KV; Gruze, A; Krauth, MT; Mayerhofer, M; Müllauer, L; Pickl, WF; Selzer, E; Sillaber, C; Valent, P; Wacheck, V1
Ashman, LK; Baleato, RM; Byrnes, EM; Griffith, R; Lyons, AB; Odell, AF; Roberts, KG1
von Mehren, M1
Bui, B; Italiano, A1
Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V1
Ashman, LK; Griffith, R; Mashkani, B1
Brandal, S; Carter, M; Kapur, R; Lee, YN; McDevitt, MA; Mendell, JT; Metcalfe, DD; Noel, P; Takemoto, CM; Wentzel, E1
Pardanani, A1
Akin, C; DeRemer, DL; Ustun, C1
Andrich, K; Dalhoff, C; Dreger, M; Fischer, JJ; Glinski, M; Graebner, OY; Koester, H; Kroll, F; Michaelis, S; Schrey, AK; Sefkow, M1
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K1
Chen, PM; Chiou, TJ; Gau, JP; Hong, YC; Hsiao, LT; Liu, CY; Liu, JH; Lu, DY; Tzeng, CH; Yu, YB1
Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V1
Ebihara, Y; Hanada, S; Imai, K; Konishi, C; Matsuzaka, E; Mochizuki, S; Nakauchi, H; Otsu, M; Takagi, H; Tsuji, K; Yamamoto, S1
Asami, Y; Crump, A; Ōmura, S1
Falchi, L; Verstovsek, S1
Fang, Q; He, Z; Lu, T; Ma, D; Wang, J; Wang, P; Wei, D; Yu, K; Yu, Z; Zhang, Y; Zhou, Z1
Manley, PW1

Reviews

5 review(s) available for staurosporine and imatinib mesylate

ArticleYear
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
    Clinical colorectal cancer, 2006, Volume: 6 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles

2006
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles

2008
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
    Leukemia research, 2011, Volume: 35, Issue:9

    Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles

2011
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
    The Journal of antibiotics, 2018, Volume: 71, Issue:8

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine

2018
Kit Mutations: New Insights and Diagnostic Value.
    Immunology and allergy clinics of North America, 2018, Volume: 38, Issue:3

    Topics: Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin; Staurosporine

2018

Other Studies

24 other study(ies) available for staurosporine and imatinib mesylate

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
    European journal of medicinal chemistry, 2018, Jun-25, Volume: 154

    Topics: Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured

2018
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
    Cancer cell, 2002, Volume: 1, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Protein Kinase C; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Staurosporine; Transfection; Tumor Cells, Cultured

2002
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
    Cancer cell, 2003, Volume: 3, Issue:5

    Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Marrow; Bone Marrow Transplantation; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Fusion Proteins, bcr-abl; Genetic Vectors; Humans; Imatinib Mesylate; Immunophenotyping; Mice; Models, Genetic; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Precipitin Tests; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retroviridae; Spleen; Staurosporine; Time Factors

2003
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Mar-02, Volume: 101, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sirolimus; Staurosporine

2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
    The Journal of biological chemistry, 2004, Dec-31, Volume: 279, Issue:53

    Topics: Animals; Benzamides; Binding Sites; Catalysis; Catalytic Domain; Crystallography, X-Ray; Enzyme Precursors; Hematopoietic Stem Cells; Humans; Hydrogen Bonding; Imatinib Mesylate; Insecta; Intracellular Signaling Peptides and Proteins; Ligands; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Staurosporine; Syk Kinase; X-Rays

2004
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Gastroenterology, 2005, Volume: 128, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine

2005
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Blood, 2005, Jul-15, Volume: 106, Issue:2

    Topics: Animals; B-Lymphocytes; Benzamides; Cell Line; DNA-Binding Proteins; Drug Resistance; Enzyme Activation; Enzyme Inhibitors; Humans; Imatinib Mesylate; Mice; Milk Proteins; Mutation; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; STAT3 Transcription Factor; STAT5 Transcription Factor; Staurosporine; Trans-Activators

2005
The hypereosinophilic syndrome: idiopathic or not, that is the question.
    Haematologica, 2005, Volume: 90, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets

2005
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
    Blood, 2006, Jan-15, Volume: 107, Issue:2

    Topics: Anti-Bacterial Agents; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; CD2 Antigens; Cell Proliferation; Cells, Cultured; Cladribine; Down-Regulation; Doxycycline; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Female; Humans; Imatinib Mesylate; Immunophenotyping; In Vitro Techniques; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Piperazines; Platelet Membrane Glycoproteins; Protein Kinase C; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tetraspanin 30

2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
    Gastroenterology, 2006, Volume: 131, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Male; Mice; Mice, Nude; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; Tyrosine; Xenograft Model Antitumor Assays

2006
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Blood, 2007, Apr-01, Volume: 109, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; DNA Primers; Drug Synergism; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligoribonucleotides, Antisense; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Staurosporine; Transfection

2007
Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Exons; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoprecipitation; Mice; Mutation; Myeloid Progenitor Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine

2007
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Veterinary immunology and immunopathology, 2009, Dec-15, Volume: 132, Issue:2-4

    Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles

2009
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
    Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5

    Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles

2010
KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
    Blood, 2011, Mar-31, Volume: 117, Issue:13

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cells, Cultured; Gene Expression Regulation; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Microphthalmia-Associated Transcription Factor; MicroRNAs; NIH 3T3 Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Staurosporine

2011
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
    American journal of hematology, 2011, Volume: 86, Issue:4

    Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles

2011
Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
    Journal of proteomics, 2011, Dec-10, Volume: 75, Issue:1

    Topics: Benzamides; Chromatography, Liquid; Dasatinib; Gene Expression Profiling; Hep G2 Cells; Humans; Imatinib Mesylate; Liver Neoplasms; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Staurosporine; Thiazoles

2011
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Journal of biochemistry, 2012, Volume: 151, Issue:1

    Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection

2012
Mast cell leukemia: an extremely rare disease.
    Journal of the Chinese Medical Association : JCMA, 2014, Volume: 77, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Male; Piperazines; Pyrimidines; Staurosporine

2014
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    Leukemia research, 2014, Volume: 38, Issue:10

    Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult

2014
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adolescent; Benzimidazoles; Cells, Cultured; Drug Evaluation, Preclinical; Hematopoiesis; Humans; Imatinib Mesylate; Imidazoles; Induced Pluripotent Stem Cells; Male; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyridazines; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Staurosporine; Translocation, Genetic

2015
Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia.
    Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup3

    Topics: Animals; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; G2 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase C-alpha; Staurosporine; Xenograft Model Antitumor Assays

2018
Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
    Chimia, 2019, Aug-21, Volume: 73, Issue:7

    Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Staurosporine

2019